Oppenheimer Asset Management Inc. Sells 56,430 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Oppenheimer Asset Management Inc. lessened its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 22.2% in the 3rd quarter, HoldingsChannel reports. The fund owned 197,199 shares of the company’s stock after selling 56,430 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Takeda Pharmaceutical were worth $2,804,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Blair William & Co. IL grew its stake in shares of Takeda Pharmaceutical by 6.5% during the first quarter. Blair William & Co. IL now owns 12,649 shares of the company’s stock valued at $176,000 after purchasing an additional 777 shares during the last quarter. Dorsey & Whitney Trust CO LLC lifted its holdings in Takeda Pharmaceutical by 4.6% during the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 18,197 shares of the company’s stock worth $253,000 after buying an additional 798 shares in the last quarter. SG Americas Securities LLC boosted its position in Takeda Pharmaceutical by 5.4% in the 1st quarter. SG Americas Securities LLC now owns 16,099 shares of the company’s stock valued at $224,000 after buying an additional 824 shares during the last quarter. Catalytic Wealth RIA LLC increased its stake in shares of Takeda Pharmaceutical by 4.0% in the 2nd quarter. Catalytic Wealth RIA LLC now owns 21,703 shares of the company’s stock valued at $281,000 after buying an additional 841 shares during the period. Finally, EverSource Wealth Advisors LLC raised its position in shares of Takeda Pharmaceutical by 38.6% during the second quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company’s stock worth $43,000 after acquiring an additional 859 shares during the last quarter. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Trading Up 0.4 %

Shares of TAK opened at $13.62 on Friday. The stock’s fifty day simple moving average is $14.24 and its 200-day simple moving average is $13.83. The company has a quick ratio of 0.77, a current ratio of 1.28 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $43.34 billion, a PE ratio of 23.48, a price-to-earnings-growth ratio of 0.26 and a beta of 0.54. Takeda Pharmaceutical Company Limited has a 12-month low of $12.57 and a 12-month high of $15.08.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.